Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
NGM Biopharmaceuticals, Inc. NGM
$3.46
-$0.28 (-7.98%)
На 18:01, 12 мая 2023
+376.88%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
310493038.00000000
-
week52high
18.25
-
week52low
2.92
-
Revenue
55333000
-
P/E TTM
-2
-
Beta
1.19672600
-
EPS
-1.85000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 20:00
Описание компании
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Buy | 20 июл 2022 г. | |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 05 ноя 2021 г. |
| BMO Capital | Outperform | Outperform | 17 сент 2021 г. |
| Raymond James | Strong Buy | Outperform | 13 сент 2021 г. |
| B. Riley Securities | Buy | Buy | 07 окт 2022 г. |
| Raymond James | Outperform | Strong Buy | 18 окт 2022 г. |
| Goldman Sachs | Neutral | Buy | 18 окт 2022 г. |
| Cowen & Co. | Outperform | Outperform | 18 окт 2022 г. |
| Piper Sandler | Neutral | Overweight | 17 окт 2022 г. |
| Jefferies | Hold | Buy | 17 окт 2022 г. |
| Raymond James | Outperform | Outperform | 04 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| COLUMN GROUP L P | A | 927231 | 176730 | 31 янв 2023 г. |
| GOEDDEL DAVID V | A | 927231 | 176730 | 31 янв 2023 г. |
| COLUMN GROUP L P | A | 750501 | 7542 | 30 янв 2023 г. |
| GOEDDEL DAVID V | A | 750501 | 7542 | 30 янв 2023 г. |
| COLUMN GROUP L P | A | 742959 | 9900 | 23 янв 2023 г. |
| GOEDDEL DAVID V | A | 742959 | 9900 | 23 янв 2023 г. |
| COLUMN GROUP L P | A | 733059 | 500 | 20 янв 2023 г. |
| GOEDDEL DAVID V | A | 733059 | 500 | 20 янв 2023 г. |
| COLUMN GROUP L P | A | 732559 | 37639 | 19 янв 2023 г. |
| GOEDDEL DAVID V | A | 732559 | 37639 | 19 янв 2023 г. |
Новостная лента
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
28 февр 2023 г. в 20:20
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 13.46% and 166.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
03 ноя 2022 г. в 20:20
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.28% and 12.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
After Plunging 59.4% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)
Zacks Investment Research
03 ноя 2022 г. в 11:22
The heavy selling pressure might have exhausted for NGM Biopharmaceuticals (NGM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
3 Best Penny Stocks To Buy Before November According To Insiders
PennyStocks
20 окт 2022 г. в 10:59
Penny stocks to buy according to insiders in October. The post 3 Best Penny Stocks To Buy Before November According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
After Plunging 76.6% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)
Zacks Investment Research
18 окт 2022 г. в 11:19
NGM Biopharmaceuticals (NGM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.